PURPOSE: Cervical tumor response on posttherapy 2[(18)F]fluoro-2-deoxy-d-glucose-positron emission tomography (FDG-PET) is predictive of survival outcome. The purpose of this study was to use gene expression profiling to identify pathways associated with tumor metabolic response. EXPERIMENTAL DESIGN: This was a prospective tissue collection study for gene expression profiling of 62 pretreatment biopsies from patients with advanced cervical cancer. Patients were treated with definitive radiation. Fifty-three patients received concurrent chemotherapy. All patients underwent a pretreatment and a 3-month posttherapy FDG-PET/computed tomography (CT). Tumor RNA was harvested from fresh frozen tissue and hybridized to Affymetrix U133Plus2 GeneChips. Gene set enrichment analysis (GSEA) was used to identify signaling pathways associated with tumor metabolic response. Immunohistochemistry and in vitro FDG uptake assays were used to confirm our results. RESULTS: There were 40 biopsies from patients with a complete metabolic response (PET-negative group) and 22 biopsies from patients with incomplete metabolic response (PET-positive group). The 3-year cause-specific survival estimates were 98% for the PET-negative group and 39% for the PET-positive group (P < 0.0001). GSEA identified alterations in expression of genes associated with the PI3K/Akt signaling pathway in patients with a positive follow-up PET. Immunohistochemistry using a tissue microarray of 174 pretreatment biopsies confirmed p-Akt as a biomarker for poor prognosis in cervical cancer. The phosphoinositide 3-kinase (PI3K) inhibitor LY294002 inhibited FDG uptake in vitro in cervical cancer cell lines. CONCLUSIONS: Activation of the PI3K/Akt pathway is associated with incomplete metabolic response in cervical cancer. Targeted inhibition of PI3K/Akt may improve response to chemoradiation.
PURPOSE: Cervical tumor response on posttherapy 2[(18)F]fluoro-2-deoxy-d-glucose-positron emission tomography (FDG-PET) is predictive of survival outcome. The purpose of this study was to use gene expression profiling to identify pathways associated with tumor metabolic response. EXPERIMENTAL DESIGN: This was a prospective tissue collection study for gene expression profiling of 62 pretreatment biopsies from patients with advanced cervical cancer. Patients were treated with definitive radiation. Fifty-three patients received concurrent chemotherapy. All patients underwent a pretreatment and a 3-month posttherapy FDG-PET/computed tomography (CT). Tumor RNA was harvested from fresh frozen tissue and hybridized to Affymetrix U133Plus2 GeneChips. Gene set enrichment analysis (GSEA) was used to identify signaling pathways associated with tumor metabolic response. Immunohistochemistry and in vitro FDG uptake assays were used to confirm our results. RESULTS: There were 40 biopsies from patients with a complete metabolic response (PET-negative group) and 22 biopsies from patients with incomplete metabolic response (PET-positive group). The 3-year cause-specific survival estimates were 98% for the PET-negative group and 39% for the PET-positive group (P < 0.0001). GSEA identified alterations in expression of genes associated with the PI3K/Akt signaling pathway in patients with a positive follow-up PET. Immunohistochemistry using a tissue microarray of 174 pretreatment biopsies confirmed p-Akt as a biomarker for poor prognosis in cervical cancer. The phosphoinositide 3-kinase (PI3K) inhibitor LY294002 inhibited FDG uptake in vitro in cervical cancer cell lines. CONCLUSIONS: Activation of the PI3K/Akt pathway is associated with incomplete metabolic response in cervical cancer. Targeted inhibition of PI3K/Akt may improve response to chemoradiation.
Authors: Christopher M Lee; Christa B Fuhrman; Vicente Planelles; Morgan R Peltier; David K Gaffney; Andrew P Soisson; Mark K Dodson; H Dennis Tolley; Christopher L Green; Karen A Zempolich Journal: Clin Cancer Res Date: 2006-01-01 Impact factor: 12.531
Authors: M Morris; P J Eifel; J Lu; P W Grigsby; C Levenback; R E Stevens; M Rotman; D M Gershenson; D G Mutch Journal: N Engl J Med Date: 1999-04-15 Impact factor: 91.245
Authors: Jason D Wright; Farrokh Dehdashti; Thomas J Herzog; David G Mutch; Phyllis C Huettner; Janet S Rader; Randall K Gibb; Matthew A Powell; Feng Gao; Barry A Siegel; Perry W Grigsby Journal: Cancer Date: 2005-12-01 Impact factor: 6.860
Authors: Patricia J Eifel; Kathryn Winter; Mitchell Morris; Charles Levenback; Perry W Grigsby; Jay Cooper; Marvin Rotman; David Gershenson; David G Mutch Journal: J Clin Oncol Date: 2004-03-01 Impact factor: 44.544
Authors: Florianne E Henken; N Sanjib Banerjee; Peter J F Snijders; Chris J L M Meijer; Johanna De-Castro Arce; Frank Rösl; Thomas R Broker; Louise T Chow; Renske D M Steenbergen Journal: Mol Cancer Date: 2011-06-10 Impact factor: 27.401
Authors: Jin Zhang; Ramachandran Rashmi; Matthew Inkman; Kay Jayachandran; Fiona Ruiz; Michael R Waters; Perry W Grigsby; Stephanie Markovina; Julie K Schwarz Journal: J Clin Invest Date: 2021-03-01 Impact factor: 14.808
Authors: Perry W Grigsby; Israel Zighelboim; Matthew A Powell; David G Mutch; Julie K Schwarz Journal: Gynecol Oncol Date: 2013-04-10 Impact factor: 5.482
Authors: Jason E McDermott; Jing Wang; Hugh Mitchell; Bobbie-Jo Webb-Robertson; Ryan Hafen; John Ramey; Karin D Rodland Journal: Expert Opin Med Diagn Date: 2013-01
Authors: Ramachandran Rashmi; Xiaojing Huang; John M Floberg; Adnan E Elhammali; Michael L McCormick; Gary J Patti; Douglas R Spitz; Julie K Schwarz Journal: Cancer Res Date: 2018-01-16 Impact factor: 12.701
Authors: Alexi A Wright; Brooke E Howitt; Andrea P Myers; Suzanne E Dahlberg; Emanuele Palescandolo; Paul Van Hummelen; Laura E MacConaill; Melina Shoni; Nikhil Wagle; Robert T Jones; Charles M Quick; Anna Laury; Ingrid T Katz; William C Hahn; Ursula A Matulonis; Michelle S Hirsch Journal: Cancer Date: 2013-08-23 Impact factor: 6.860
Authors: Michael Zorniak; Paul A Clark; Heather E Leeper; Matthew D Tipping; David M Francis; Kevin R Kozak; M Shahriar Salamat; John S Kuo Journal: Clin Cancer Res Date: 2012-05-15 Impact factor: 12.531